Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 4Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Penile Neoplasms 1Pathologic Complete Response 1Mesothelioma, Malignant 1Lung Neoplasms 1Brain Neoplasms 1

Interventions

Docetaxel 17Surveys and Questionnaires 15pembrolizumab 14Specimen Handling 10Radiotherapy 10Early Intervention, Educational 10Zoledronic Acid 9Interviews as Topic 9olaparib 8Standard of Care 8Psychiatric Rehabilitation 8Therapeutics 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Fulvestrant 7durvalumab 6Paclitaxel 6Nivolumab 6Methods 6Educational Status 6Carboplatin 6enzalutamide 5Trastuzumab 5Radiosurgery 5Exercise 5Cyclophosphamide 5palbociclib 4Taxes 4Sirolimus 4Letrozole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Platinum × Breast × Clear all
NCT06769425 2025-06-24

HS-10502

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
157 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡